• Sat. Nov 19th, 2022

010 LKKJ

Learn today, build tomorrow

Illumina Revenues and Revenue Growth from 2012 to 2016

Byadmin

Nov 6, 2022
Illumina Revenues

This report shows the growth and revenues of Illumina Inc (ILMN) over the five years from 2012 to 2016. Illumina had $2.4 billion in total revenues in 2016. Illumina saw a revenue increase of 8% over the previous year. The fiscal year ending in December is reflected in the revenues and revenue growth.

Illumina Revenues: 2012 to 2016

Illumina’s revenues and growth details for the past five years.

In 2012, Illumina generated $1.1 Billion in revenues. Illumina saw an 8.8% increase in revenues year-over-year in 2012.

Illumina had $1.4 Billion in revenues in 2013. Illumina saw a 23.7% increase in revenues year-over-year in 2013.

In 2014, Illumina had a total revenue of $1.9 trillion. Illumina saw a 31% increase in revenues year-over-year during 2014.

In 2015, Illumina had a total revenue of $2.2 million. Illumina saw a 19.3% increase in revenues year-over-year in 2015.

In 2016, Illumina had $2.4 Billion in revenues. Illumina saw an 8% increase in revenues year-over-year during 2016.

How to Analyze Revenue Growth

The most common financial metric is revenue growth. Revenue growth is the percentage increase or decrease in revenue for a company between two periods. The following formula is used to calculate it: (revenues during period two – revenue during period one)/revenues during period one)*100. The revenue growth year-over-year is calculated if the periods are consecutive. If the periods are two consecutive quarters, the revenue growth is referred to as the quarterly revenue growth quarter-over-quarter. Revenue growth refers to quarterly revenue growth year over year if the periods are the same quarter in both consecutive years. If the periods are not consecutive, the revenue CAGR (Commutative Annual Growth Rate) is calculated.
talentfavorite.net
mystroydom.net
nikeshoxonlinestore.com
margitkocsis.org
ppgeoufpa.net

For many reasons, revenue growth analysis is critical. It helps to understand how a company is performing. Favorable revenue growth rates indicate that the business is doing well and revenues are rising. If they are negative, it is a sign that revenues are falling, and the company must take steps to increase them. The company will shrink if they don’t. A company’s past revenue growth analysis, market size, and market share analysis can be used to forecast future revenues. Third, it is possible to compare a company’s growth rate with its competitors. This helps determine who is winning more business. Market share increases when revenue growth is higher than the industry average. High revenue growth rates are the best indicators of industry disruption.

Illumina Ranking

Illumina was ranked 849 in the R&P Research ranking of the top 300 public companies in the US based on 2016 revenues. Every one of the top 3000 companies earned more than $50,000,000 in annual revenues in 2016.

These were the top 20 US companies by revenue in 2016.

Walmart ($482.1 million)

ExxonMobil ($226.1 million)

Berkshire Hathaway ($223.6 million)

Apple ($215.6 Billion)

McKesson (190.9 billion)

UnitedHealth Group ($184.8 million)

CVS Health ($177.5 million)

General Motors ($166.4 Billion)

AT&T ($163.8 billion)

Ford Motor (£151.8 billion).

AmerisourceBergen ($146.8 billion)

Amazon ($136 billion).

Verizon ($126 billion).

General Electric (123.7 billion)

Cardinal Health ($121.5 million)

Costco ($118.7 billion)

Walgreens Boots Alliance ($117.4 Billion)

Chevron ($114.5 billion)

Kroger ($109.8 Billion)

Express Scripts Holding ($100.3 Billion)

R&P Research assigns each company to one sector and one business industry in order to benchmark their performance. An industry is a group of businesses with similar business models. A sector is a collection of similar/related industries. To facilitate high-level analysis, similar sectors are divided into sector groups.

The Healthcare sector includes, for example, the Life Sciences and Services sectors. The Life Sciences sector includes the following industries: Pharmaceuticals, Medical Devices, Biotechnology, Diagnostics & Scientific Instruments. Healthcare Services include the following industries: Medication Stores and PBM and Distributors; Healthcare Payers, Healthcare Providers; Medical Software Services; Healthcare Research Services.

Illumina is associated with the Healthcare Sector Group and Life Sciences Sector.

Illumina was ranked number 78 with $2.4 billion in revenues. In 2016, 290 public companies generated more than $50 million in revenue in the US Healthcare group.

These were the top 10 US healthcare sector companies by revenue in 2016.

McKesson (190.9 billion)

UnitedHealth Group ($184.8 million)

CVS Health ($177.5 million)

AmerisourceBergen ($146.8 billion)

Cardinal Health ($121.5 million)

Walgreens Boots Alliance ($117.4 Billion)

Express Scripts Holding ($100.3 Billion)

Anthem (84.9 billion USD)

J&J ($71.9 billion)

Aetna ($63.2 million)

The Healthcare sector group includes the following sectors: Life Sciences and Healthcare Services.

Illumina was 38th out of all companies in the US Life Sciences industry with $2.4 billion in revenues. In 2016, 197 companies were publicly traded in the US Life Sciences market and had more than $50 million revenues.

These were the top 10 companies in the US Life Sciences industry by revenue in 2016.

J&J ($71.9 billion)

Pfizer ($52.8 Billion)

Merck ($39.8 Billion)

Gilead Sciences ($30.4 Billion)

Medtronic ($28.8 Billion)

Abbvie ($25.6 billion)

Amgen ($23 billion)

Eli Lilly ($21.2 Billion)

Abbott Laboratories ($20.9 billion)

Bristol Myers Squibb (19.4 Billion)

The Life Sciences sector includes the following industries: Pharmaceuticals, Medical Devices, Biotechnology, Diagnostics & Scientific Instruments. These are the definitions of each industry:

The pharmaceuticals industry comprises companies that develop, manufacture, and market medications. These companies generally offer prescription and over-the-counter pharmaceutical products. Many pharmaceutical companies offer a wide range of services, products, and solutions for animal health. Diverse pharmaceutical companies can operate in multiple segments, including consumer health products and medical devices.

The Medical Equipments industry comprises manufacturers and distributors of medical equipment. Large-scale capital equipment such as X-ray machines, MRI scanners, and another non-disposable medical device like pacemakers and stents are all medical equipment. Manufacturers of disposable medical supplies, such as contact lenses, eyeglass lenses, and bandages, include Medical Supplies.

The Biotechnology Industry comprises Biotechnology product companies, subscription companies, and service companies. Biotechnology products sell pharmaceutical medications made from, extracted from, semi-synthesized, or partially synthesized in biological sources. Companies that subscribe to the service model create genome databases that can be used for developing medicinal drugs. Services companies provide solutions based on the same technology or generic tool used by large pharmaceutical and biopharmaceutical corporations.

Diagnostics & Scientific Instruments industry is made up of companies that offer diagnostic reagents, instruments, and testing products to help diagnose and treat various diseases. This includes companies that produce, market, and sell diagnostic tests, diagnostic systems, and related products and services. Companies that produce and market diagnostic instruments, equipment, consumables, and reagents for research, manufacturing, and analysis are also included.

Illumina ranked 6th among all US Diagnostics & Scientific Instruments companies with $2.4 billion in revenues. In 2016, 22 companies generated more than $50 million in revenues.

In 2016, the top 10 companies in the US Diagnostics & Scientific Instruments industry by revenue were:

Thermo Fisher Scientific (18.3 billion)

Quest Diagnostics ($7.5 Billion)

Agilent Technologies ($4.2 million)

Hologic ($2.8 Billion)

Mettler Toledo (2.5 billion dollars)

Illumina ($2.4 billion)

Waters ($2.2 Billion)

PerkinElmer ($2.1 billion)

Bio-Rad ($2.1 billion)

OPKO Health ($1.2 million)

Segmentation Companies

R&P Research divides companies into segments based on revenues, revenue growth, and net profit margins. This allows them to identify and analyze companies with high/low growth and the most/least profitable companies of similar size in different industries or sectors.

The following four segments are based on the company’s annual revenue:

Mega companies with revenues exceeding $50 billion

Companies with revenues between $10 billion to $50 billion are considered very large.

Large companies with revenues between $1 billion to $10 billion

Companies of mid-size with revenues between $50 Million and $1 Billion

Illumina had $2.4 billion in revenues in 2016. In 2016, 1097 companies fell within the Large companies revenue category.

The following eight segments are based on the company’s annual revenue growth:

Companies with a very high positive growth rate, with more than 50% annual revenue growth.

Companies with high positive growth have annual revenue growth of between 20% and 50%.

Companies with medium positive growth, which have an annual revenue growth of between 5% to 20%

Companies with low positive growth, which have an annual revenue growth of between 0% to 5%

Companies with low negative growth have annual revenue growth of -5% to 0%.

Companies with medium negative growth or annual revenue growth between -20% and -5%.

Companies with high negative growth have annual revenue growth of between -50% to -20%.

Companies with very high negative growth or annual revenue growth of less than -50%.

Illumina saw an 8% increase in revenue year-over-year during 2016. In 2016, 876 companies fell within the Medium positive growth segment. Of the top 3000 US companies, approximately two-thirds had positive revenue growth, while only 1015 had negative revenue growth.

The companies are classified based on their annual net profit margin.

Companies with a very high positive margin have a net profit margin of more than 50%.

Companies with high positive margins, which have a net profit margin between 20% to 50%

Companies with medium positive margins, where the net profit margin is between 5% to 20%

Companies with a low positive margin have a net profit margin of between 0% and 5%.

Companies with low negative margins, which have a net profit margin between 5% and 0%

Companies with medium negative margins, with net profit margins between -20% to -5%.

Companies with high negative margins, with net profit margins between -50% to -20%.

Companies with very high negative margins, with a net profit margin of less than -50%.

Illumina had a net margin of 19.3% in 2016. In 2016, 1086 companies fell within the Medium positive segment of the net profit margin. The US top-3000 companies had 1086 companies in the Medium positive net margin segment during 2016. 2244 (nearly 34% of the total) had a positive net profit margin, and 756 (nearly 14% of the total) had a negative net profit margin during 2016.

Summary of Company Business

Illumina, Inc. offers array-based and sequencing solutions for genetic analysis. Its sequencing by synthesizer technology allows researchers to use it for various purposes and can be used to sequence mammalian genes. The arrays can be used for various deoxyribonucleic acids and RNA analysis applications such as single nucleotide genotyping, copy number variations, gene expression, and methylation analysis. They also allow for detecting and identifying known genetic markers on one array. The company also offers sequencing and library preparation kits that can be used to speed up analysis and simplify workflows. It also provides non-invasive prenatal testing and genotyping services, genome sequencing, and genotyping. It is available to genomic research centers, universities, government laboratories, hospitals, pharmaceuticals, biotechnology, commercial molecular diagnostic labs, and consumer genomics companies.

The company distributes its products to customers in North America, Europe, Latin America, and Asia-Pacific, as well as through life-science distributors. It has agreements with IBM Watson Health for genome data interpretation, integrating Watson for genomics into Illumina BaseSpace Sequence Hub and the tumor sequencing process. NRGene for new molecular breeding tools to support global food production. A co-development agreement was also signed with Munich Leukemia Laboratory GmbH (IBM Watson Health) to develop a prototype of cognitive technology to aid researchers in improving leukemia treatment. Illumina, Inc. was established in 1998. It is headquartered in San Diego, California.

DATASTORE

The R&P Research Industry Intelligence Platform sourced the chart and data for this page. This platform gives the financial metrics for all public companies in the United States. Users can compare the financial data for a company’s last five to 15 years with other companies and industry averages. This benchmarking exercise can provide powerful insights to help you make better business decisions.